Thai buy expands Fuji's production base and hones DKSH's market expansion focus
This article was originally published in Scrip
Japan's Fuji Pharma has agreed to pay around ¥4.2 billion ($53.6 million) to acquire the largest facility in Thailand for the contract manufacture of pharmaceuticals, in a deal that will also relieve current owner DKSH of a non-core asset.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.